Stephanie Lynn Sandefur

Title: The Innovative Contributions of Stephanie Lynn Sandefur

Introduction

Stephanie Lynn Sandefur is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of antibodies. With a total of 3 patents to her name, Sandefur is recognized for her dedication to advancing medical science.

Latest Patents

Sandefur's latest patents focus on methods of treating cancer using anti-CD137 antibodies. The first patent describes antibodies that bind to human CD137 and display agonist activity, which are useful for treating both solid and hematological tumors, either alone or in combination with chemotherapy and ionizing radiation. The second patent also relates to anti-CD137 antibodies with similar applications in cancer treatment. These inventions highlight her commitment to improving therapeutic options for patients battling cancer.

Career Highlights

Stephanie Lynn Sandefur is currently employed at Eli Lilly and Company, a leading pharmaceutical company known for its innovative research and development in healthcare. Her work at Eli Lilly has allowed her to collaborate with some of the brightest minds in the industry, further enhancing her contributions to medical science.

Collaborations

Some of her notable coworkers include Christopher Carl Frye and Michael Dewain Kalos. Their collaborative efforts have played a crucial role in advancing the research and development of cancer treatments.

Conclusion

Stephanie Lynn Sandefur's innovative work in the field of cancer treatment exemplifies her dedication to improving patient outcomes. Her patents and collaborations reflect her significant impact on medical research and development.